What Is Urine Fibrosis? Causes, Symptoms, and Treatment

Urine fibrosis is not a single diagnosis you will find in a medical textbook. It is an informal umbrella term for fibrotic conditions that affect the urinary tract, from the kidneys down through the ureters, bladder, and urethra. In each of these locations, the core problem is the same: normal, flexible tissue gets replaced by dense scar-like material, stiffening the organ and impairing its ability to do its job. The causes range from chronic infections and surgical trauma to radiation therapy and autoimmune inflammation, and the consequences can be as mild as urinary frequency or as severe as kidney failure.

What Fibrosis Actually Does to Urinary Tissue

Fibrosis in the urinary system is characterized by abnormal buildup of extracellular matrix proteins, particularly collagen, along with infiltration by specialized scar-forming cells called myofibroblasts. This process replaces the normal elastic tissue with a stiff, collagen-heavy matrix that reduces the tissue’s ability to stretch and contract.¹ In the kidney, this means impaired filtration. In the bladder, it means a smaller, stiffer organ that cannot hold urine properly. In the urethra, it means narrowing that obstructs urine flow.

A signaling molecule called TGF-β plays a central role in driving fibrosis throughout the urinary tract. It is generally considered the key mediator of fibrotic disease, though researchers have also discovered it has some protective functions, making it a complicated target for treatment.² Tissue stiffness itself also feeds the problem. When tissue begins to stiffen from early fibrosis, that mechanical change cooperates with TGF-β to accelerate further scarring, creating a self-reinforcing cycle.³

Where Fibrosis Strikes in the Urinary System

Fibrosis can develop at every level of the urinary tract. Each location produces distinct problems, and a person can have fibrosis in more than one site simultaneously.

Kidney (Renal Fibrosis)

Renal fibrosis is the final common pathway of chronic kidney disease regardless of what originally injured the kidneys. Whether the initial trigger was diabetes, high blood pressure, autoimmune disease, or obstruction, the end result tends to look the same under a microscope: scarred, stiffened kidney tissue that can no longer filter blood effectively.⁴ Tubulointerstitial fibrosis, which involves the small tubes and surrounding tissue of the kidney, is considered the best predictor of whether kidney disease will keep getting worse.⁵ Chronic kidney disease currently affects roughly ten percent of the global population, and progressive fibrosis is at the heart of why it advances.

Research into the immune cells involved has found that certain natural killer cells accumulate in fibrotic kidney tissue at much higher numbers than in healthy kidneys. One particular subset of these cells correlated with the loss of kidney function, suggesting the immune system’s own activity contributes to the scarring process.⁶

Bladder Fibrosis

When fibrosis develops in the bladder wall, the organ loses its ability to expand during filling and contract during urination. The abnormal deposition of connective tissue throughout the bladder wall layers results in a low-volume, high-pressure bladder that can ultimately contribute to kidney scarring and failure because urine backs up toward the kidneys.⁷ A common cause is bladder outlet obstruction, such as from an enlarged prostate. When the bladder has to push against chronic resistance, it goes through distinct phases: first inflammation, then muscle thickening as it tries to overcome the blockage, and eventually decompensation into fibrosis when the muscle can no longer cope.⁸

Radiation therapy for pelvic cancers is another well-recognized cause. The radiation-induced ischemia (reduced blood flow) stimulates progressive fibrosis of the bladder wall, which in severe cases shrinks bladder capacity enough to cause incontinence.⁹

Urethral Strictures

Fibrosis of the urethra produces strictures, areas of narrowing where scar tissue has replaced the normal urethral lining. About 45% of urethral strictures are caused by medical or surgical procedures (catheterization, endoscopy, prostate surgery), roughly 30% have no identifiable cause, and about 20% result from bacterial infections.¹⁰ Because the population is aging and more people are undergoing urological procedures, urethral strictures are expected to become more common.

Retroperitoneal Fibrosis

Retroperitoneal fibrosis is a rare condition in which fibrous tissue forms in the space behind the abdominal organs, often wrapping around the aorta and compressing the ureters. When the ureters get squeezed, urine cannot drain from the kidneys, causing hydronephrosis (swelling of the kidneys from backed-up urine).¹¹ In one hospital series, hydronephrosis was found in half of all retroperitoneal fibrosis cases at diagnosis.¹² The condition can be idiopathic (no known cause) or secondary to medications, infections, prior surgery, or malignancy.

Common Causes and Risk Factors

The triggers for urinary tract fibrosis vary by location, but they share a common thread: some form of injury or chronic insult that kicks off an overactive wound-healing response. Instead of repairing tissue and stopping, the healing process overshoots and keeps laying down collagen indefinitely.¹

Chronic obstruction: An enlarged prostate, kidney stones, or a congenital abnormality that blocks urine flow creates sustained mechanical stress on upstream tissue, eventually leading to fibrosis in the bladder or kidneys.
Surgical and procedural trauma: Catheter insertion, endoscopy, and prostate or pelvic surgery can damage the urethra or ureters, triggering scar formation.
Radiation therapy: Pelvic radiation for prostate, cervical, or colorectal cancer damages blood vessels in the bladder and surrounding tissue, leading to ischemia-driven fibrosis that can appear months or even years after treatment.
Chronic infection and inflammation: Repeated urinary tract infections, bacterial urethritis, and autoimmune conditions can sustain the inflammatory signals that push tissue toward fibrosis.
Diabetes and hypertension: These are the two most common drivers of chronic kidney disease globally, and both promote renal fibrosis through long-term vascular and metabolic damage.

Symptoms to Watch For

Urinary tract fibrosis is often silent in its early stages. Symptoms tend to emerge once the structural changes have progressed enough to interfere with organ function, which is part of why the condition is frequently diagnosed later than ideal. What you experience depends heavily on where the fibrosis is located.

Kidney fibrosis may produce no noticeable symptoms until kidney function has dropped substantially. At that point, you might notice fatigue, swelling in the legs or face, changes in urine output, or foamy urine. Advanced cases lead to the full spectrum of chronic kidney disease symptoms, including nausea, difficulty concentrating, and itching.

Bladder fibrosis tends to announce itself through urinary frequency, urgency, difficulty fully emptying the bladder, and in more severe cases, incontinence. As the bladder wall stiffens and loses capacity, even small volumes of urine create uncomfortable pressure.¹³ Progressive collagen buildup restricts the ability of the bladder muscle to relax, so a small amount of filling produces disproportionately high pressure.

Urethral strictures produce a noticeably weak or split urine stream, straining to urinate, a feeling of incomplete emptying, and sometimes urinary retention. Retroperitoneal fibrosis often presents more vaguely with dull flank or abdominal pain, leg swelling, and constitutional symptoms like fatigue and weight loss. The kidney-related symptoms only appear once the ureters have been compressed enough to cause significant obstruction.

The impact on daily life can be considerable. Research on patients with radiation-related bladder problems and chronic pelvic pain has documented high levels of quality-of-life deterioration, with reported impairment in self-esteem, social functioning, and emotional well-being that in some cases matched the severity seen in patients with other serious urological conditions.

How Urinary Fibrosis Is Diagnosed

There is no single “fibrosis test” you can take. Diagnosis typically involves a combination of imaging, lab work, and sometimes tissue biopsy, guided by which part of the urinary tract is suspected.

For retroperitoneal fibrosis, CT scan is the most frequently used diagnostic tool, picking up the condition in over 90% of cases in one hospital series, while ultrasound identified it in about 60%.¹² MRI and contrast-enhanced CT are considered the investigations of choice, though biopsy is recommended for definitive confirmation, especially to rule out malignancy.¹⁴

For renal fibrosis, the gold standard remains kidney biopsy, where a pathologist can directly assess the degree of tubulointerstitial scarring. Biopsy carries its own risks, though, so researchers have been actively seeking blood and urine biomarkers that could detect fibrosis without an invasive procedure.¹⁵ One promising candidate is uromodulin, a protein produced by kidney tubule cells and excreted in urine. Higher levels of urinary uromodulin have been associated with lower severity of tubulointerstitial fibrosis, suggesting it could serve as a non-invasive marker.¹⁶ In mouse models, uromodulin staining was lower in fibrotic kidneys than in normal or repaired ones, supporting the idea that declining uromodulin levels could flag developing fibrosis.

Bladder fibrosis is often diagnosed through urodynamic studies that measure how the bladder fills and empties, combined with cystoscopy (a camera inserted into the bladder). Urethral strictures are typically identified with urethrography or cystoscopy, both of which can visualize the narrowed segment directly. Increased collagen and elastin deposition in the bladder wall can alter the organ’s biomechanical properties, causing decreased compliance that shows up on urodynamic testing.¹⁷

Treatment Options

Treating urinary fibrosis is challenging because scar tissue, once deposited, is difficult to reverse. Most current treatments focus on managing the obstruction or inflammation that drives the fibrosis rather than dissolving the scar tissue itself.

Medical Therapy

For retroperitoneal fibrosis, the mainstay of medical treatment is immunosuppressive therapy. A combination of corticosteroids with mycophenolate mofetil has shown encouraging results in small case series: systemic symptoms resolved in all treated patients, roughly nine out of ten patients had meaningful shrinkage of the fibrotic mass, and most obstructed ureters became free of obstruction after about a year and a half of therapy. Recurrence was uncommon.¹⁸ Tamoxifen and azathioprine have also been used in combination with steroids.¹⁹

A systematic review with meta-analysis comparing different treatment approaches for idiopathic retroperitoneal fibrosis found no statistically significant difference between regimens when it came to fibrosis regression, freedom from ureteral stents, relapse rates, or clinical improvement.²⁰ This does not mean the treatments do not work; rather, the disease is rare enough that no single approach has accumulated strong comparative data. In practice, the choice of immunosuppressive agent often comes down to physician experience and patient tolerance of side effects.

For renal fibrosis driven by chronic kidney disease, treatment centers on controlling the underlying condition, whether that means tighter blood sugar management for diabetes, blood pressure control, or treating autoimmune kidney diseases with appropriate immunosuppression. There is no approved drug that directly reverses kidney fibrosis in humans, though several targets are under investigation.

Surgical and Procedural Approaches

When fibrosis causes physical obstruction, mechanical relief becomes necessary. For retroperitoneal fibrosis compressing the ureters, ureteral stents are the most commonly performed drainage procedure, though their long-term efficacy is debated. Open ureterolysis, in which a surgeon physically frees the ureters from the surrounding fibrous tissue, remains the gold standard surgical treatment. Laparoscopic and robotic techniques have been reported as feasible alternatives, but no prospective comparative trials exist because the disease is so uncommon.²¹

For urethral strictures, treatment options range from simple dilation (stretching the narrowed area) to internal urethrotomy (cutting the scar from the inside) to formal urethroplasty (surgically reconstructing the urethra with healthy tissue). The recurrence rate after dilation and urethrotomy is high for anything beyond short, simple strictures, making urethroplasty the preferred option for longer or recurrent strictures.

Bladder fibrosis from radiation or chronic obstruction has fewer satisfying surgical options. In extreme cases where the bladder has become too small and stiff to function, augmentation cystoplasty (enlarging the bladder with a segment of intestine) or even urinary diversion may be necessary.

The Role of Stents in Preventing Fibrosis

Interestingly, stents are not only used to relieve existing obstruction but may also help prevent fibrosis from developing after urinary tract injury. Animal research has shown that placing a ureteral stent after ureteral injury significantly reduced inflammatory cell infiltration and collagen deposition, with the protective effect being most pronounced in more severe injuries. At both two and four weeks after surgery, stented groups showed less inflammation and fibrosis compared with unstented groups.²² This has practical implications for surgical decision-making: when the ureter is injured during pelvic surgery or other procedures, early stenting could reduce the likelihood of a fibrotic stricture forming later.

Fibrosis in Children With Urinary Obstruction

Urinary fibrosis is not exclusively an adult problem. Congenital obstructive nephropathy, where a baby is born with a blockage somewhere in the urinary system, accounts for the largest share of chronic kidney disease in children.²³ The obstruction triggers a cascade of events in the developing kidney: cells undergo abnormal changes and die off, forming non-functional structures. This progresses to interstitial inflammation and fibrosis, both of which impair growth of the affected kidney. The healthy kidney on the other side compensates by growing larger, but the fibrotic kidney continues to deteriorate unless the obstruction is relieved early enough.

The tricky part for pediatric urologists is determining which children with prenatal or neonatal hydronephrosis will go on to develop significant fibrosis and which will resolve on their own. Many mild obstructions self-correct, but waiting too long in the cases that do not can cost irreplaceable kidney tissue. This remains one of the more difficult judgment calls in pediatric urology.

Experimental Approaches and Stem Cell Research

Given the limitations of current treatments, there is strong interest in therapies that could actually reverse established fibrosis rather than just slow its progression. Stem cell therapy is one area generating attention. Preclinical studies have shown that stem cells from various sources can reduce the accumulation of extracellular matrix and alleviate renal fibrosis in animal models, with improvements in kidney function observed alongside reduced scarring.²⁴ The mechanisms appear to involve both direct replacement of damaged cells and indirect effects through the release of anti-inflammatory and anti-fibrotic molecules.

Clinical translation is still in early stages. Human studies on stem cell therapy for renal fibrosis are limited, and questions about optimal cell type, delivery route, dosing, and long-term safety remain unanswered. Other experimental strategies focus on interrupting the TGF-β signaling pathway or targeting the mechanical stiffness feedback loop that perpetuates fibrosis, but the dual protective and harmful roles of TGF-β in the kidney make this a tricky target.² Block it too aggressively and you risk losing its beneficial immune-regulating functions. The research is promising but still far from producing an anti-fibrosis pill you can pick up at a pharmacy.

Why Early Detection Matters So Much

Perhaps the most important practical point about urinary fibrosis is that it is far easier to prevent or slow than to reverse. Once dense scar tissue has replaced functional organ tissue, no current treatment reliably restores what was lost. This makes early identification of the conditions that lead to fibrosis, and prompt management of those conditions, the most effective strategy available.

For people with risk factors like diabetes, hypertension, recurrent urinary infections, or a history of pelvic radiation, regular monitoring of kidney function and urinary symptoms can catch fibrotic changes before they become advanced. Urinary biomarkers like uromodulin may eventually make non-invasive screening more practical, but for now, standard blood tests for kidney function, imaging when symptoms suggest obstruction, and urodynamic testing when bladder function seems impaired remain the core tools. If you have been told you have early chronic kidney disease or bladder changes after radiation, the evidence strongly favors aggressive management of the underlying cause rather than a wait-and-see approach, because fibrosis tends to be a one-way street once it gets momentum.

1
PubMed Central. Fibrotic Diseases of the Human Urinary and Genital Tract: Current Understanding and Potential Strategies for Treatment
2
PubMed Central. TGF-β signaling in the kidney: profibrotic and protective effects
3
PubMed Central. YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis
4
PubMed. Diagnostic and prognostic biomarkers for tubulointerstitial fibrosis
5
Heliyon. What Is Urine Fibrosis? Causes, Symptoms, and Treatment
6
PubMed. Interferon-γ production by tubulointerstitial human CD56(bright) natural killer cells contributes to renal fibrosis and chronic kidney disease progression
7
Journal of Urology. MOLECULAR ANALYSIS OF COLLAGENS IN BLADDER FIBROSIS
8
PubMed. Bladder outlet obstruction: progression from inflammation to fibrosis
9
PubMed Central. Urological complications after radiation therapy—nothing ventured, nothing gained: a Narrative Review
10
PubMed Central. Urethral stricture: etiology, investigation and treatments
11
International Journal of Surgery Case Reports. Extensive primary retroperitoneal fibrosis (Ormond’s disease) with common bile duct and ureteral obstruction: A rare case report
12
PubMed. Clinical features, diagnosis, and management of retroperitoneal fibrosis in a university referral hospital and literature review
13
Chinese Nursing Research. Correlation between bladder compliance and the content of detrusor collagen fibers
14
PubMed Central. Retroperitoneal fibrosis-the long and winding path.
15
PubMed Central. Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review
16
PubMed Central. Urine Uromodulin as a Biomarker of Kidney Tubulointerstitial Fibrosis
17
PubMed Central. Progressive bladder remodeling due to bladder outlet obstruction: a systematic review of morphological and molecular evidences in humans
18
PubMed Central. Medical management of retroperitoneal fibrosis
19
PubMed. Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches
20
PubMed Central. Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis
21
PubMed Central. Management of idiopathic retroperitoneal fibrosis from the urologist’s perspective
22
PubMed Central. The protective role of ureteral stents in reducing fibrosis and preventing stricture in ureteral injuries of different severities
23
PubMed. Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy
24
PubMed Central. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis